Clinical Trials Logo

Alopecia Areata clinical trials

View clinical trials related to Alopecia Areata.

Filter by:

NCT ID: NCT05324293 Completed - Clinical trials for Androgenetic Alopecia

To Evaluate the Safety, Tolerability and Efficacy in Male and Female With AGA Treated With HMI-115 Over a 24-week Treatment Period

Start date: May 11, 2022
Phase: Phase 1
Study type: Interventional

An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.

NCT ID: NCT05296863 Completed - Clinical trials for Alopecia, Androgenetic

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

Start date: October 11, 2021
Phase: Phase 3
Study type: Interventional

This study investigated the efficacy of adipose derived stem cell conditioned media (ADSC-CM) combined with minoxidil for hair regeneration therapy in male AGA.

NCT ID: NCT05278858 Terminated - Alopecia Areata Clinical Trials

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

Start date: March 24, 2022
Phase: Phase 4
Study type: Interventional

This is an interventional pilot study assessing the tolerability of needle-free delivery administration of ILTA with the Med-Jet as an alternative to conventional syringe and needle in patients with patchy pediatric alopecia areata. There will be a total of four (4) or five (5) visits necessary for study participation. The investigators hypothesize that the Med-Jet will have acceptable pain tolerability, efficacy, safety, and a positive impact on patient quality of life.

NCT ID: NCT05255237 Recruiting - Alopecia Areata Clinical Trials

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

AA
Start date: March 25, 2022
Phase: Phase 3
Study type: Interventional

This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".

NCT ID: NCT05251831 Completed - Alopecia Areata Clinical Trials

Comparative Study Efficacy and Safety of of Activated Versus Non-Activated PRP

Start date: February 1, 2020
Phase: Early Phase 1
Study type: Interventional

This was comparative prospective study conducted on 40 subjects, diagnosed with alopecia areata of 40 the scalp, carried in a period from February 2020 and March 2021

NCT ID: NCT05244980 Completed - Clinical trials for Alopecia, Androgenetic

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).

NCT ID: NCT05218642 Completed - Alopecia Clinical Trials

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Start date: January 31, 2022
Phase: Phase 2
Study type: Interventional

The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.

NCT ID: NCT05213936 Recruiting - Alopecia Clinical Trials

Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color

Start date: October 24, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate hairstyling techniques aimed at increasing efficacy of scalp cooling in the prevention of chemotherapy-induced alopecia, determine scalp cooling effect on persistent chemotherapy-induced alopecia, and elucidate molecular mechanisms and predictive biomarkers associated with scalp cooling success in patients with skin of color receiving chemotherapy for breast or non-small cell lung cancer. This study is being conducted because prior studies have found scalp cooling to be highly effective in preventing hair loss resulting from chemotherapy. However, minority representation was largely limited in completed trials. A recent study found that scalp cooling devices are less efficacious in patients with skin of color, likely because patients with skin of color have hair is predominantly types 3 (curly) and 4 (kinky), which tend to become bulkier when wet and can interfere with scalp cooling cap fitting. The investigators plan to test two techniques aimed at improving scalp cooling efficacy in patients with skin of color through hairstyling methods that minimize hair volume in order to increase cooling cap to scalp contact: 1) cornrows/braids/twists or 2) water/conditioner emulsion on hair. Preliminary data show that breast cancer patients with type 3 or 4 hair receiving taxane chemotherapy and scalp cooling using these techniques to prepare the hair for scalp cooling cap fitting all experienced hair preservation. Additionally, the investigators will also assess persistent chemotherapy-induced alopecia outcomes and incidence by following patients up to 6 months after completing treatment. Finally, specific gene expression changes in taxane-induced chemotherapy-induced alopecia in vitro have been described previously. The investigators will test the hypothesis that scalp cooling reverses such changes in chemotherapy-induced alopecia, assess for biomarkers predictive for scalp cooling success, and investigate persistent chemotherapy-induced alopecia molecular mechanisms using non-invasive transcriptome sequencing on plucked hair follicles.

NCT ID: NCT05210452 Not yet recruiting - Alopecia Clinical Trials

Treatment of Alopecia Using Follicular Stem Cells

Start date: March 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of alopecia using the injections of cultured stem cells from human hair follicles,(which contain epithelial and mesenchymal cells stem cell)

NCT ID: NCT05205070 Recruiting - Alopecia Areata Clinical Trials

A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

AZURE
Start date: December 22, 2021
Phase: Phase 2
Study type: Interventional

Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata